Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Go back to Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 196.58 -2.09 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $198.67 | 52 Week High | $333.65 | |||
| Open | $200.22 | 52 Week Low | $223.02 | |||
| Day High | $200.99 | P/E | 25.17 | |||
| Day Low | $193.20 | EPS | $7.81 | |||
| Volume | 1,729,827 | |||||
| (NASDAQ: DNLI) | Delayed: 23.31 -0.18 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.49 | 52 Week High | $ | |||
| Open | $24.17 | 52 Week Low | $ | |||
| Day High | $24.65 | P/E | N/A | |||
| Day Low | $23.21 | EPS | $ | |||
| Volume | 2,518,393 | |||||
